Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.


Journal

Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355

Informations de publication

Date de publication:
06 2019
Historique:
received: 06 10 2018
revised: 06 02 2019
accepted: 14 02 2019
pubmed: 18 3 2019
medline: 30 1 2020
entrez: 18 3 2019
Statut: ppublish

Résumé

To unravel the hierarchy of cellular/molecular pathways in the disease tissue of early, treatment-naïve rheumatoid arthritis (RA) patients and determine their relationship with clinical phenotypes and treatment response/outcomes longitudinally. 144 consecutive treatment-naïve early RA patients (<12 months symptoms duration) underwent ultrasound-guided synovial biopsy before and 6 months after disease-modifying antirheumatic drug (DMARD) initiation. Synovial biopsies were analysed for cellular (immunohistology) and molecular (NanoString) characteristics and results compared with clinical and imaging outcomes. Differential gene expression analysis and logistic regression were applied to define variables correlating with treatment response and predicting radiographic progression. Cellular and molecular analyses of synovial tissue demonstrated for the first time in early RA the presence of three pathology groups: (1) We demonstrate at disease presentation, prior to pathology modulation by therapy, the presence of specific cellular/molecular synovial signatures that delineate disease severity/progression and therapeutic response and may pave the way to more precise definition of RA taxonomy, therapeutic targeting and improved outcomes.

Identifiants

pubmed: 30878974
pii: annrheumdis-2018-214539
doi: 10.1136/annrheumdis-2018-214539
pmc: PMC6579551
doi:

Substances chimiques

Antirheumatic Agents 0
Biomarkers 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

761-772

Subventions

Organisme : Medical Research Council
ID : G0800648
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K015346/1
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : 20670
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

Références

Arthritis Rheumatol. 2018 Jun;70(6):841-854
pubmed: 29439295
Ann Rheum Dis. 2015 Mar;74(3):611-7
pubmed: 24336336
Sci Transl Med. 2013 Mar 27;5(178):178ra40
pubmed: 23536012
Nat Rev Rheumatol. 2016 Dec;12(12):731-742
pubmed: 27784891
Arthritis Res Ther. 2010;12(5):R196
pubmed: 20961415
Stat Med. 1990 Jul;9(7):811-8
pubmed: 2218183
Lancet. 2017 Jun 10;389(10086):2328-2337
pubmed: 28612747
Arthritis Res Ther. 2011 Mar 24;13(2):R51
pubmed: 21435232
Ann Rheum Dis. 2009 Feb;68(2):279-82
pubmed: 18765428
Am J Epidemiol. 2014 Aug 1;180(3):318-24
pubmed: 24966219
Ann Rheum Dis. 1994 Jan;53(1):39-44
pubmed: 8311554
Arthritis Res Ther. 2014 Apr 25;16(2):R103
pubmed: 24766912
J Immunol. 2018 Jul 15;201(2):417-422
pubmed: 29891556
Curr Opin Rheumatol. 2013 May;25(3):334-44
pubmed: 23492740
Trans Am Clin Climatol Assoc. 2017;128:24-43
pubmed: 28790485
Nat Rev Rheumatol. 2013 Jan;9(1):24-33
pubmed: 23147896
Arthritis Rheumatol. 2018 May;70(5):690-701
pubmed: 29468833
Arthritis Rheum. 2010 Jun;62(6):1602-7
pubmed: 20178127
Arthritis Rheum. 2003 Aug;48(8):2132-45
pubmed: 12905466
Arthritis Res Ther. 2012 Feb 07;14(1):R30
pubmed: 22314025
Arthritis Rheumatol. 2016 Apr;68(4):805-16
pubmed: 26554541
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Genet. 2016 Apr;48(4):407-16
pubmed: 26928227
Arthritis Rheum. 2002 Aug;46(8):2034-8
pubmed: 12209505
Ann Rheum Dis. 2008 Jul;67(7):1017-22
pubmed: 17921183
PLoS Med. 2009 Jan 13;6(1):e1
pubmed: 19143467
Arthritis Res Ther. 2014;16(2):R90
pubmed: 25167216
Arthritis Res Ther. 2014 Sep 24;16(5):434
pubmed: 25249397
Ann Rheum Dis. 2005 Jun;64(6):834-8
pubmed: 15576415

Auteurs

Frances Humby (F)

Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.

Myles Lewis (M)

Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.

Nandhini Ramamoorthi (N)

Biomarker Discovery OMNI, Genentech Inc, South San Francisco, California, USA.

Jason A Hackney (JA)

Bioinformatics and Computational Biology, Genentech Inc, South San Francisco, California, USA.

Michael R Barnes (MR)

Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
Centre for Translational Bioinformatics, William Harvey Research Institute, London, UK.

Michele Bombardieri (M)

Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.

A Francesca Setiadi (AF)

Biomarker Discovery OMNI, Genentech Inc, South San Francisco, California, USA.

Stephen Kelly (S)

Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.

Fabiola Bene (F)

Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.

Maria DiCicco (M)

Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.

Sudeh Riahi (S)

Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.

Vidalba Rocher (V)

Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.

Nora Ng (N)

Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.

Ilias Lazarou (I)

Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.

Rebecca Hands (R)

Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.

Désirée van der Heijde (D)

Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands.

Robert B M Landewé (RBM)

Amsterdam Rheumatology Center, AMC, Amsterdam, Netherlands.
Department of Rheumatology, Zuyderland MC, Heerlen, Netherlands.

Annette van der Helm-van Mil (A)

Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands.

Alberto Cauli (A)

Universita degli Studi di Cagliari, Cagliari, Italy.

Iain McInnes (I)

Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

Christopher Dominic Buckley (CD)

University of Birmingham, Birmingham, UK.

Ernest H Choy (EH)

Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Peter C Taylor (PC)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Kennedy Institute of Rheumatology, Oxford, UK.

Michael J Townsend (MJ)

Biomarker Discovery OMNI, Genentech Inc, South San Francisco, California, USA c.pitzalis@qmul.ac.uk townsend.michael@gene.com.

Costantino Pitzalis (C)

Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK c.pitzalis@qmul.ac.uk townsend.michael@gene.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH